S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease

Key facts

Sponsor

SWOG Cancer Research Network

Principal Investigator

Ellen R. Gaynor, MD, MD

Loyola University

Intervention

bleomycin sulfate(biological)

Enrollment

11 enrolled

Eligibility

15-65 years · All sexes

Timeline

2000 – 2005

Study locations (30)

• Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States
• University of California San Diego Cancer Center, La Jolla, California, United States
• Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States
• UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
• CCOP - Christiana Care Health Services, Wilmington, Delaware, United States
• Lombardi Cancer Center, Washington D.C., District of Columbia, United States
• Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
• CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
• Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
• University of Chicago Cancer Research Center, Chicago, Illinois, United States
• Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States
• Veterans Affairs Medical Center - Togus, Togus, Maine, United States
• Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · Eastern Cooperative Oncology Group · Cancer and Leukemia Group B

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07275216
  Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07209059
  PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
  National Research Center for Hematology, Russia
• RECRUITINGPHASE2NCT06984146
  Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
  National Medical Research Radiological Centre of the Ministry of Health of Russia
• RECRUITINGPHASE2NCT06745076
  Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
  University of Washington
• RECRUITINGPHASE1, PHASE2NCT06642792
  A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
  Akeso
• RECRUITINGPHASE2NCT06377540
  MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
  Masonic Cancer Center, University of Minnesota
• RECRUITINGPHASE2NCT07234487
  Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
  St. Petersburg State Pavlov Medical University
• RECRUITINGPHASE2NCT06812858
  PD-1 Inhibitors Maintenance for cHL Post-autoHCT
  St. Petersburg State Pavlov Medical University

See all trials for Classic Hodgkin lymphoma →